Bispecific Antibodies Market

Bispecific Antibodies Market (5th Edition): Distribution by Therapeutic Area, Mechanism of Action, Target Antigen, Antibody Format, Key Players and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

Lowest Price Guaranteed From USD 5,899
Published
May 2023
Pages
391
View Count
22607
Buy Now

Example Insights

Report Description

Bispecific Antibody Therapeutics Market Overview

Bispecific antibodies (BsAbs) represent a novel class of antibodies that act by simultaneously attaching to two separate / distinct antigens or different epitopes of the same antigen. These drugs primarily function by redirecting immune effector cells to effectively eliminate cancer cells using various mechanisms, such as antibody-dependent cell mediated cytotoxicity (ADCC), antibody dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). Further, bispecific antibody drugs possess unique biological and pharmacological characteristics and are available in a wide range of formats, making them a promising option for therapeutic use. It is worth mentioning that, till date, nine bispecific antibodies have been approved for therapeutic use; these are (arranged in reverse chronological order of their initial approval) Tecvayli™ (October 2022), Nanozora® (September 2022), AK104 (June 2022), Lunsumio® (June 2022), VABYSMO™ (February 2022), KIMMTRAK® (January 2022), RYBREVANT™ (May 2021), Hemlibra® (November 2017) and Blincyto® (December 2014). Additionally, in the last few years, a definite surge in clinical trials being conducted to evaluate bispecific antibodies has been observed, given the rising popularity and potential therapeutic benefits of such candidates. In the foreseen future, as more such therapeutic candidates move into the clinical stage and / or receive approval, we anticipate the bispecific antibody therapeutics market to witness healthy growth.

Key Market Insights

The Bispecific Antibodies Market (5th Edition): Distribution by Therapeutic Area (Autoimmune Disorders, Genetic Disorders, Hematological Malignancies, Ophthalmic Disorders, Skin Cancers And Solid Tumors), Mechanism of Action (Cytokines Retargeting / Neutralization, Dual Ligands Blocking, Resistance Factors Co-Targeting, Targeting Tumor Angiogenesis, T-Cell Retargeting / Activation and Others), Target Antigen (C5-Albumin, CD20 x CD3, CD3 x BCMA, CD3 x CD19, EGFR x cMET, EpCAM x CD3, Factor IXa x Factor X, gp100 x CD3, HER2 x HER2, PD-1 x CTLA-4, PD-L1 x TGFβ, TNF-α x HAS, VEGF x DLL4 and VEGF-A x ANG2), Antibody Format (Asymmetric And Fragments), Key Players (Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Janssen Research & Development, Linton Pharm, Merck, OncXerna Therapeutics, Pfizer, Roche, Taisho Pharmaceutical and Zymeworks) and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players involved in the development and manufacturing of bispecific therapeutic antibodies for treating various oncological and non-oncological disorders. The report answers many key questions related to this domain.

Rising Interest in Bispecific Antibody Therapeutics

The growing pipeline of bispecific antibodies and the increasing number of associated clinical trials to evaluate the effectiveness of such candidates indicate a high level of interest and investment in this field. The recent approval of several bispecific antibodies by regulatory agencies has increased the interest and confidence of stakeholders in this approach. 2022 saw approval of six bispecific antibodies, with Janssen being the latest to receive FDA approval for Tecvayli™ (in October 2022) for the treatment of multiple myeloma. It is worth mentioning that the potential advantages of bispecific antibodies over traditional monoclonal antibodies, such as increased efficacy and specificity, have made them an attractive option for the treatment of a wide range of diseases.

Pipeline Analysis of Bispecific Antibodies

Bispecific antibody landscape features the presence of over 120 large, mid-sized and small drug developers. It is worth mentioning that, currently, over 220 bispecific antibodies are either approved or being evaluated in clinical stages of development, whereas over 180 candidates are in preclinical stages of development. In addition, we came across various contract manufacturing / research organizations that are engaged in this domain.

Bispecific Antibodies are Mainly Targeting Cancer

The increasing prevalence of chronic diseases, such as oncological disorders, autoimmune disorders and infectious diseases, is expected to drive the market for bispecific antibody therapeutics. Such therapeutics offer a promising approach by targeting multiple disease pathways, simultaneously. Currently, there are more than 15 bispecific antibodies in development for the treatment of gastric cancer. In March 2023, Akeso Biopharma announced the completion of enrollment for a phase III trial for Cadonilimab for use in combination with chemotherapy as first-line therapy for advanced gastric or gastroesophageal junction cancer. It is also worth highlighting that the most recent approval of Tecvayli™ for relapsed or refractory multiple myeloma has expanded the target indications where bispecific antibodies have proven their efficacy.

Market Size of the Bispecific Antibodies Market

Driven by the rising interest in R&D activities and growing demand for effective therapeutics, the bispecific antibody therapeutics market is anticipated to witness an annualized growth rate of over 9.5%, during the period 2023-2035. Specifically, in terms of therapeutic areas, the market is anticipated to be driven by drugs targeting oncology disorders. In addition, presently, close to 64% of the market is captured by players based in North America and Europe.

Key Players in the Bispecific Antibodies Market

Examples of key players engaged in this domain (which have also been captured in this report, arranged in alphabetical order) include Akeso Biopharma, Amgen, Astrazeneca, Genmab, Immunocore, Janssen Research & Development, Merck, Roche and Zymeworks. Roche is playing a key role in taking the bispecific antibodies from development to commercialization, with three approvals to date. Two of these approvals came in 2022 – Vabysmo™ in February 2022 and Tecvayli™ in October 2022. Another of Roche’s bispecific antibody, Glofitamab, received priority review from FDA for the treatment of relapsed or refractory large b-cell lymphoma and is likely to receive approval soon.

Big Pharma Showing Keen Interest in Bispecific Antibody

Examples of recent partnerships signed by big pharma players engaged in this domain (which have also been captured in this report, arranged in reverse chronological order of the agreement year) include a product licensing agreement between GSK and Wuxi Biologics (January 2023), a product commercialization agreement signed between Genentech and Biogen (December 2022), a product licensing agreement between Sanofi and Innate Pharma (December 2022) and a product development and commercialization agreement signed between Regeneron and CytomX Therapeutics (November 2022).

Scope of the Report

Key Report Attributes	Details
Forecast Period	2023 – 2035
Therapeutic Areas	Autoimmune Disorders Genetic Disorders Hematological Malignancies Ophthalmic Disorders Skin Cancers Solid Tumors
Mechanisms of Action	Cytokines Retargeting / Neutralization Dual Ligands Blocking Resistance Factors Co-targeting Targeting Tumor Angiogenesis T-Cell Retargeting / Activation Others
Target Antigens	C5-Albumin CD20 x CD3 CD3 x BCMA CD3 x CD19 EGFR x cMET EpCAM x CD3 Factor IXa x Factor X gp100 x CD3 HER2 x HER2 PD-1 x CTLA-4 PD-L1 x TGFβ TNF-α x HSA VEGF x DLL4 VEGF-A x ANG2
Antibody Formats	Asymmetric Fragments
Key Players	Akeso Biopharma Alexion Amgen Genmab Immunocore Janssen Research & Development Linton Pharm Merck OncXerna Therapeutics Pfizer Roche Taisho Pharmaceutical Zymeworks
Key Geographical Regions	North America Europe Asia Rest of the World

The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

An executive summary of the key insights captured during our research, offering a high-level view on the current state of the bispecific antibodies market and its likely evolution in the short to mid and long term.
A brief introduction to bispecific antibodies, highlighting their historical background, as well as information on their structure, different types available, unique antibody formats, mechanisms of action of various products and their applications.
A detailed review of the market landscape of over 220 bispecific antibodies that are either approved or being evaluated in different stages of clinical development, based on several relevant parameters, such as developer company, phase of development, target antigen, type of therapy, route of administration, method of administration, target indication, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer.
An in-depth assessment of the market landscape of over 180 bispecific antibodies that are currently being evaluated in preclinical studies, based on several relevant parameters, such as developer company, stage of development, target antigen, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer.
An insightful analysis, highlighting the contemporary market trends in the bispecific antibody therapeutics domain, through six different graphical representations, including various representations of clinical and approved bispecific antibodies based on phase of development and route of administration, phase of development and disease segment and phase of development and location of their headquarters. In addition, this chapter includes various representations of preclinical stage bispecific antibody therapeutics based on stage of development and disease segment and stage of development and location of their headquarters; the chapter also includes representation of the developers of bispecific antibody therapeutics based on stage of development (preclinical, clinical and preclinical and clinical) of their drug candidates and location of their headquarters.
A detailed assessment of over 80 technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics, featuring a 3-D comparative bubble analyses of bispecific antibody technology platforms based on multiple relevant parameters, such as clinical / preclinical pipeline strength, developer’s years of experience, company size and location of headquarters of developers.
An in-depth analysis of big pharma players engaged in this domain, featuring insightful spider web analyses of such players, based on clinical stage competition, marketed drugs competition, clinical trial activity, partnership activity and technology portfolio strength. Additionally, it features heat map analyses, highlighting the comparison of big pharma players based on various relevant parameters, such as target antigen, antibody format, mechanism of action and target therapeutic area.
Elaborate profiles of prominent drug developers engaged in the development of bispecific antibodies , featuring a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key members of the executive team, financial details / information (if available), drug portfolio, recent developments and an informed future outlook.
An insightful analysis of various partnerships inked between stakeholders engaged within the bispecific antibody therapeutics domain, during the period 2016-2023, based on several relevant parameters, such as year of partnership, type of partnership, disease segment, type of payment model employed, deal amount, most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity.
A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, this section includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs), highlighting the key considerations for bispecific antibody developers, while selecting a suitable CRO / CMO.
An in-depth analysis of ongoing and planned studies related to bispecific antibody therapeutics, which were registered till April 2023, taking into consideration several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, type of study, study design, type of sponsor / collaborator, leading industry and non-industry players, key focus areas and geographical location of trials.
A review of regulatory guidelines issued by the ICH, WHO and FDA for the development of bispecific antibodies. In addition, it provides details related to the responses of various pharmaceutical industries to the FDA guidelines.
A review of different channels used for promoting marketed bispecific antibodies , along with examples of players that have undertaken such initiatives, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies (chosen based on their popularity in this domain), namely Blincyto® and Hemlibra®, and comparison of both the drugs based on information available on their respective websites.
A comprehensive market forecast analysis, including future sales projections of bispecific antibodies that are either marketed or under phase III of clinical development, till the year 2035, presenting a detailed market segmentation on the basis of therapeutic areas (autoimmune disorders, genetic disorders, hematological malignancies, ophthalmic disorders, skin cancers and solid tumors), mechanism of action (cytokines retargeting / neutralization, dual ligands blocking, resistance factors co-targeting, targeting tumor angiogenesis, t-cell retargeting / activation and others), Target Antigen (C5-Albumin, CD20 x CD3, CD3 x BCMA, CD3 x CD19, EGFR x cMET, EpCAM x CD3, Factor IXa x Factor X, gp100 x CD3, HER2 x HER2, PD-1 x CTLA-4, PD-L1 x TGFβ, TNF-α x HAS, VEGF x DLL4 and VEGF-A x ANG2), antibody format (asymmetric and fragments), key players (Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Janssen Research & Development, Linton Pharm, Merck, OncXerna Therapeutics, Pfizer, Roche, Taisho Pharmaceutical and Zymeworks) and key geographical regions (North America, Europe, Asia and Rest of the World).
A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall market.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders (in alphabetical order of company name):

Siobhan Pomeroy (Former Senior Director, Business Development, CytomX Therapeutics)
Jane Dancer (Business Development Consultant, F-star)
Ran Salomon (Senior Scientist, Immunai)
Yinjue Wang (Director, GMP Clinical Manufacturing, Innovent Biologics)
Ludger Große-Hovest (Founder and Chief Scientific Officer, SYNIMMUNE) and Martin Steiner (Chief Executive Officer, SYNIMMUNE)
Francesca Rosato (PhD Student, University of Freiburg)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is a bispecific antibody?
Answer: Bispecific antibody refers to a novel antibody that possesses the dual action ability to attach to two different epitopes, or antigens, at the same time.

Question 2: What are the key factors driving bispecific antibodies market?
Answer: Recent approval of several bispecific antibody therapeutics, increased efficacy / specificity compared to traditional monoclonal antibodies, rising prevalence of chronic disorders, growing number of clinical trials evaluating such drugs and high partnership activity in this domain are expected to drive the bispecific antibody therapeutics market in the coming decade.

Question 3: Which are the top players in bispecific antibody therapeutics market?
Answer: Top players in bispecific antibodies market include include Akeso Biopharma, Amgen, Astrazeneca, Genmab, Immunocore, Janssen Research & Development, Merck, Roche and Zymeworks.

Question 4: What are the most common antigens targeted by bispecific antibody therapeutics?
Answer: Target antigens, such as CD20 x CD3, PD-1 x CTLA-4 and PD-L1 x CTLA-4, emerged as the most popular antigens targeted by various bispecific antibody drugs.

Question 5: What are the most popular technology platforms being employed for the development of bispecific antibody therapeutics?
Answer: Currently, over 80 antibody technology platforms are being employed for the development of such therapeutics. Among such platforms, BiTE® (Amgen), CRIB™ (Alphamab Oncology), CrossMab™ (Roche), DuoBody® (Genmab), Knobs-into-Holes (Genentech) and XmAb® (Xencor) emerged as the most popular antibody technology platforms.

Question 6: What is the global market size of the bispecific antibody therapies market, in 2035?
Answer: Bispecific antibody therapies market is anticipated to have a market size of over USD 16 billion in 2035.

Question 7: What is the growth rate (CAGR) of the bispecific antibody therapies market?
Answer: Bispecific antibody therapies market is anticipated to grow at a CAGR of over 9.5%, during the period 2023-2035.

Question 8: Which region has the highest growth rate in bispecific antibody therapeutics market?
Answer: In terms of regions, Asia is likely to grow at the highest CAGR during the period 2023-2035.

Question 9: What are the most common therapeutic area(s) targeted by bispecific antibody therapeutics?
Answer: Based on current and future market trends, majority of bispecific antibody therapeutics are to be developed for the treatment of oncological disorders.

Question 10: What are the partnership and collaboration trends in bispecific antibody therapeutics domain?
Answer: Currently, product development and commercialization agreements, and R&D agreements are the most common types of partnerships being inked by stakeholders engaged in the bispecific antibody therapeutics domain.

Question 11: What are the upcoming trends in bispecific antibody therapies market?
Answer: The industry is presently witnessing the rising interest towards bispecific antibody therapies which is evident from the fact that seven such drug candidates have been approved in the past year. In the future, more such approvals in the market are expected to happen, as a number of drug candidates, currently in phase III clinical studies, have shown promising results.

Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Antibodies
3.2.1. Structure
3.2.2. Functions
3.2.3. Mechanism of Action

3.3. Antibody Therapeutics
3.3.1. Historical Evolution of Antibody Therapeutics
3.3.2. Key Approved Antibody Therapeutics
3.3.3. Advanced Antibody Therapeutics
3.3.3.1. Fc Engineered and Glycoengineered Antibodies
3.3.3.2. Antibody Fragments
3.3.3.3. Fusion Proteins
3.3.3.4. Intrabodies
3.3.3.5. Bispecific Antibodies

3.4. Bispecific Antibody Formats
3.4.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
3.4.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
3.4.1.2. Bispecific Single-Domain Antibody Fusion Proteins
3.4.1.3. Diabodies / Diabody Derivatives
3.4.1.4. Fusion Proteins
3.4.1.5. Fusion Proteins Devoid of Fc Regions

3.4.2. Immunoglobulin G Based Formats (Fc Dependent Antibody Formats)
3.4.2.1. Quadromas
3.4.2.2. Knobs-Into-Holes
3.4.2.3. Dual Variable Domain Ig
3.4.2.4. IgG-scFv
3.4.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
3.4.2.6. Half Molecule Exchange
3.4.2.7. κλ- Bodies

3.5. Mechanism of Action of Bispecific Antibody Therapeutics
3.5.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
3.5.2. Directly Targeting Malignant / Tumor Cells
3.5.3. Retargeting of Toxins
3.5.4. Targeting Tumor Angiogenesis
3.5.5. Other Mechanisms

3.6. Applications of Bispecific Antibodies

4. MARKET LANDSCAPE OF APPROVED AND CLINICAL THERAPIES
4.1. Chapter Overview
4.2. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Antigen
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Method of Administration
4.2.6. Analysis by Target Indication
4.2.7. Analysis by Therapeutic Area
4.2.8. Analysis by Disease Segment

4.3. Approved and Clinical Bispecific Antibody Therapeutics: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. MARKET LANDSCAPE OF PRECLINICAL THERAPIES
5.1. Chapter Overview
5.2. Preclinical Bispecific Antibody Therapeutics: Overall Market Landscape
5.2.1. Analysis by Stage of Development
5.2.2. Analysis by Target Antigen
5.2.3. Analysis by Disease Segment

5.3. Preclinical Bispecific Antibody Therapeutics: Overall Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. KEY INSIGHTS
6.1. Chapter Overview
6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
6.2.1. Analysis by Phase of Development and Route of Administration
6.2.2. Analysis by Phase of Development and Disease Segment
6.2.3. Analysis by Phase of Development and Location of Developer’s Headquarters

6.3. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Key Insights
6.3.1. Analysis by Stage of Development and Therapeutic Area
6.3.2. Analysis by Stage of Development and Location of Developer Headquarters

6.4. Bispecific Antibody Therapeutics Developers Landscape: Key Insights
6.4.1. Distribution by Stage of Development
6.4.2. Distribution by Stage of Development and Region of Developer Headquarters

7. TECHNOLOGY ASSESSMENT FRAMEWORK
7.1. Chapter Overview
7.2. Bispecific Antibody Therapeutics: List of Technology Platforms

7.3. Bispecific Antibody Technology Platforms: Comparative Analysis
7.3.1. Analysis by Technologies for Approved and Clinical Drugs
7.3.2. Analysis by Technologies for Preclinical Drugs

7.4. Most Popular Technology Platforms: Analysis by Stage of Development
7.5. Bispecific Antibody Technology Platform Developers: Analysis by Location of Headquarters

8. BIG PHARMA PLAYERS: BENCHMARKING ANALYSIS
8.1. Chapter Overview
8.2. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)

8.3. Big Pharma Players: Comparative Clinical Pipeline Analysis
8.3.1. Analysis by Target Antigen
8.3.2. Analysis by Antibody Format
8.3.3. Analysis by Mechanism of Action
8.3.4. Analysis by Therapeutic Area

9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Akeso Biopharma
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Drug Portfolio
9.2.4. Recent Developments and Future Outlook

9.3. Alphamab Oncology
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Drug Portfolio
9.3.4. Recent Developments and Future Outlook

9.4. Amgen
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Drug Portfolio
9.4.4. Recent Developments and Future Outlook

9.5. Merck
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Drug Portfolio
9.5.4. Recent Developments and Future Outlook

9.6. Regeneron
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Drug Portfolio
9.6.4. Recent Developments and Future Outlook

9.7. Roche
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Drug Portfolio
9.7.4. Recent Developments and Future Outlook

9.8. Xencor
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Drug Portfolio
9.8.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Disease Segment
10.3.5. Analysis by Type of Payment Model Employed and Deal Amount
10.3.6. Analysis by Year of Agreement, Type of Payment Model Employed and Deal Amount
10.3.7. Analysis by Disease Segment, Type of Payment Model Employed and Deal Amount
10.3.8. Most Active Players: Analysis by Number of Partnership Instances
10.3.9. Most Popular Technologies: Analysis by Number of Partnership Instances
10.3.10. Analysis by Region
10.3.11. Intercontinental and Intracontinental Agreements

11. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS
11.1. Chapter Overview
11.2. Manufacturing of Bispecific Antibody Therapeutics
11.2.1. Key Considerations for Manufacturing and Associated Challenges
11.2.2. Contract Manufacturing Organizations (CMOs)
11.2.2.1. Bispecific Antibody Therapeutics: List of CMOs

11.2.3. Contract Research Organizations (CROs)
11.2.3.1. Bispecific Antibody Therapeutics: List of CROs

11.3. Key Considerations for Selecting a Suitable CMO / CRO Partner

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology

12.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.3. Analysis by Trial Phase
12.3.4. Analysis of Enrolled Patient Population by Trial Phase
12.3.5. Analysis by Trial Recruitment Status
12.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
12.3.7. Analysis by Type of Study
12.3.8. Analysis by Study Design
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Leading Industry Players: Analysis by Number of Registered Trials
12.3.11. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
12.3.13. Analysis by Geography
12.3.14. Analysis by Trial Recruitment Status and Geography
12.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

13. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES
13.1. Chapter Overview
13.2. Guidelines Issued by Regulatory Authorities
13.2.1. US Food and Drug Administration (FDA)
13.2.1.1. Pharma Companies’ Response to the FDA Draft Guidance

13.2.2. World Health Organization (WHO)

14. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES
14.1. Chapter Overview
14.2. Key Channels Used for Promotional Campaigns
14.2.1. Product Websites
14.2.2. Patient Assistance Programs
14.2.3. Participation in Conferences
14.2.4. Collaboration with Stakeholders
14.2.5. Drug Approval Across Multiple Geographies

14.3. Other Channels Used for Promotional and Marketing Strategies
14.4. Summary: Promotional and Marketing Strategy Leveraged by Bispecific Antibody Developers

14.5. Promotional Analysis: Blincyto®
14.5.1. Drug Overview
14.5.2. Product Website analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.1.1. For MRD Positive B cell precursor ALL
14.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Strategies
14.5.4.1. Presence in Conferences

14.6. Promotional Analysis: Hemlibra®
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
14.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
14.6.2.3. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.3.1. Co-pay Program
14.6.3.2. Independent Co-pay Assistance Foundation
14.6.3.3. Genentech Patient Foundation
14.6.4. Other Promotional Strategies
14.6.4.1. Presence in Conferences

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology and Key Assumptions

15.4. Global Bispecific Antibody Therapeutics Market, 2023-2035
15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action, 2023 and 2035
15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Target Antigen, 2023 and 2035
15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Format, 2023 and 2035
15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players, 2023 and 2035
15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Geography, 2023 and 2035

15.5. Bispecific Antibody Market: Value Creation Analysis
15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts

15.6.1. AK104 (Akeso Biopharma)
15.6.1.1. Target Patient Population
15.6.1.2. Sales Forecast
15.6.1.3. Net Present Value
15.6.1.4. Value Creation Analysis

15.6.2. Blincyto™ (Amgen)
15.6.2.1. Target Patient Population
15.6.2.2. Sales Forecast
15.6.2.3. Net Present Value
15.6.2.4. Value Creation Analysis

15.6.3. Hemlibra® (Roche)
15.6.3.1. Target Patient Population
15.6.3.2. Sales Forecast
15.6.3.3. Net Present Value
15.6.3.4. Value Creation Analysis

15.6.4. Kimmtrak® (Immunocore)
15.6.4.1. Target Patient Population
15.6.4.2. Sales Forecast
15.6.4.3. Net Present Value
15.6.4.4. Value Creation Analysis

15.6.5. Lunsumio® (Roche)
15.6.5.1. Target Patient Population
15.6.5.2. Sales Forecast
15.6.5.3. Net Present Value
15.6.5.4. Value Creation Analysis

15.6.6. Nanozora® (Taisho Pharmaceutical)
15.6.6.1. Target Patient Population
15.6.6.2. Sales Forecast
15.6.6.3. Net Present Value
15.6.6.4. Value Creation Analysis

15.6.7. Rybrevant™ (Janssen Research & Development)
15.6.7.1. Target patient Population
15.6.7.2. Sales Forecast
15.6.7.3. Net Present Value
15.6.7.4. Value Creation Analysis

15.6.8. Tecvayli™ (Janssen Research & Development)
15.6.8.1. Target Patient Population
15.6.8.2. Sales Forecast
15.6.8.3. Net Present Value
15.6.8.4. Value Creation Analysis

15.6.9. Vabysmo™ (Roche)
15.6.9.1. Target Patient Population
15.6.9.2. Sales Forecast
15.6.9.3. Net Present Value
15.6.9.4. Value Creation Analysis

15.6.10. AK112 (Akeso Biopharma)
15.6.10.1. Target Patient Population
15.6.10.2. Sales Forecast
15.6.10.3. Net Present Value
15.6.10.4. Value Creation Analysis

15.6.11. ALXN1720 (Alexion)
15.6.11.1. Target Patient Population
15.6.11.2. Sales Forecast
15.6.11.3. Net Present Value
15.6.11.4. Value Creation Analysis

15.6.12. GEN3013 (Genmab)
15.6.12.1. Target Patient Population
15.6.12.2. Sales Forecast
15.6.12.3. Net Present Value
15.6.12.4. Value Creation Analysis

15.6.13. Glofitamab (Roche)
15.6.13.1. Target Patient Population
15.6.13.2. Sales Forecast
15.6.13.3. Net Present Value
15.6.13.4. Value Creation Analysis

15.6.14. LP000 (Linton Pharm)
15.6.14.1. Target Patient Population
15.6.14.2. Sales Forecast
15.6.14.3. Net Present Value
15.6.14.4. Value Creation Analysis

15.6.15. M7824 (Merck)
15.6.15.1. Target Patient Population
15.6.15.2. Sales Forecast
15.6.15.3. Net Present Value
15.6.15.4. Value Creation Analysis

15.6.16. OMP 305B83 (Mereo BioPharma)
15.6.16.1. Target Patient Population
15.6.16.2. Sales Forecast
15.6.16.3. Net Present Value
15.6.16.4. Value Creation Analysis

15.6.17. PF-06863135 (Pfizer)
15.6.17.1. Target Patient Population
15.6.17.2. Sales Forecast
15.6.17.3. Net Present Value
15.6.17.4. Value Creation Analysis

15.6.18. ZW25 (Zymeworks)
15.6.18.1. Target Patient Population
15.6.18.2. Sales Forecast
15.6.18.3. Net Present Value
15.6.18.4. Value Creation Analysis

15.7. Concluding Remarks

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.2.1. Enhanced Specificity
16.2.2. Diverse Application Areas
16.2.3. Lower Drug Resistance
16.2.4. Success of Approved Products

16.3. Weaknesses
16.3.1. Uncertainties with Safety of Therapeutic Candidates
16.3.2. Complex Purification and Downstream Processing
16.3.3. Dimerization in Antibodies with Fc-region

16.4. Opportunities
16.4.1. Life Cycle Management of Novel Therapies
16.4.2. Growing Number of High Value Partnerships
16.4.3. Expertise Available with Contract Manufacturing Organizations
16.4.4. Emergence of Advanced Technologies

16.5. Threats
16.5.1. Rise in Attrition Rate of Clinical Stage Candidates

16.6. Concluding Remarks

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. CytomX Therapeutics
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Siobhan Pomeroy, Former Senior Director, Business Development

18.3. F-star
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Jane Dancer, Business Development Consultant

18.4. Immunai
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Ran Salomon, Senior Scientist

18.5. Innovent Biologics
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Yinjue Wang, Director, GMP Clinical Manufacturing

18.6. SYNIMMUNE
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Ludger Große-Hovest, Founder and Chief Scientific Officer, and Martin Steiner, Chief Executive Officer

18.7. University of Freiburg
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Francesca Rosato, PhD Student

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1. Historical Evolution of Antibody Therapeutics
Figure 3.2. Basic Structure of an Antibody
Figure 3.3. Revenues of Top 15 Drugs, 2022 (USD Billion)
Figure 3.4. Symmetric and Asymmetric Bispecific Antibodies
Figure 4.1. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 4.2. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Figure 4.3. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Type of Therapy
Figure 4.4. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Route of Administration
Figure 4.5. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Method of Administration
Figure 4.6. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Figure 4.7. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Figure 4.8. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Figure 4.9. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Figure 4.11. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Figure 5.1. Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Figure 5.2. Preclinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Figure 5.3. Preclinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Figure 5.4. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Figure 5.5. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Figure 5.6. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Figure 6.1. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Route of Administration
Figure 6.2. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Disease Segment
Figure 6.3. Approved and Clinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Phase of Development and Location of Developer Headquarters
Figure 6.4. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Stage of Development and Therapeutic Area
Figure 6.5. Preclinical Stage Bispecific Antibody Therapeutics Landscape: Distribution by Stage of Development and Location of Developer Headquarters
Figure 6.6. Bispecific Antibody Therapeutics Developers Landscape: Distribution by Stage of Development
Figure 6.7. Bispecific Antibody Therapeutics Developers Landscape: Distribution by Stage of Development and Region of Developer Headquarters
Figure 7.1. Technology Platforms for Approved and Clinical Bispecific Antibodies: Comparative Analysis
Figure 7.2. Technology Platforms for Preclinical Bispecific Antibodies: Comparative Analysis
Figure 7.3. Most Popular Technology Platforms: Distribution by Stage of Development
Figure 7.4. Bispecific Antibody Technology Platform Developers: Distribution by Location of Headquarters
Figure 8.1. Big Pharma Players: Benchmarking Analysis (Spider Web Representation)
Figure 8.2. Big Pharma Players: Distribution by Target Antigen
Figure 8.3. Big Pharma Players: Distribution by Antibody Format
Figure 8.4. Big Pharma Players: Distribution by Mechanism of Action
Figure 8.5. Big Pharma Players: Distribution by Therapeutic Area
Figure 9.1. Akeso Biopharma: Annual Revenues, 2019 - 2022 (RMB Million)
Figure 9.2. Alphamab Oncology: Annual Revenues, 2019 - H1 2022 (RMB Million)
Figure 9.3. Amgen: Annual Revenues, 2019 - 2022 (USD Billion)
Figure 9.4. Merck: Annual Revenues, 2019 - H1 2022 (EUR Billion)
Figure 9.5. Regeneron: Annual Revenues, 2019 - 2022 (USD Billion)
Figure 9.6. Roche: Annual Revenues, 2019 - 2022 (CHF Million)
Figure 9.7. Xencor: Annual Revenues, 2019 - 2022 (USD Million)
Figure 10.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2023
Figure 10.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4. Partnerships and Collaborations: Distribution by Disease Segment
Figure 10.5. Partnerships and Collaborations: Distribution by Type of Payment Model Employed and Deal Amount (USD Billion)
Figure 10.6. Partnerships and Collaborations: Year-wise Distribution by Type of Payment Model Employed and Deal Amount (USD Billion, 2016-2023)
Figure 10.7. Partnerships and Collaborations: Distribution by Disease Segment, Type of Payment Model Employed and Deal Amount (USD Billion)
Figure 10.8. Most Active Players: Distribution by Number of Partnership Instances
Figure 10.9. Most Popular Technologies: Distribution by Number of Partnership Instances
Figure 10.10. Partnerships and Collaborations: Distribution by Region
Figure 10.11. Partnerships and Collaborations: International and Intracontinental Agreements
Figure 12.1. Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2010-2023
Figure 12.2. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2010-2023
Figure 12.3. Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.4. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 12.5. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 12.6. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Figure 12.7. Clinical Trial Analysis: Distribution by Type of Study
Figure 12.8. Clinical Trial Analysis: Distribution by Study Design
Figure 12.9. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.10. Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.11. Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.12. Clinical Trial Analysis: Key Focus Areas (Word Cloud Representation)
Figure 12.13. Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 12.14. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Figure 12.15. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Recruitment Status
Figure 13.1. FDA Considerations for Development of Bispecific Antibodies
Figure 14.1. Key Channels Used for Promotional and Marketing Campaigns
Figure 14.2. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, BLAST Study Results)
Figure 14.3. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, TOWER Study Results)
Figure 14.4. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, Ph (+) Relapsed / Refractory B-cell Precursor ALL)
Figure 14.5. Blincyto®: Product Website Snapshots (Messages for Healthcare Professionals, Relapsed / Refractory B-cell Precursor ALL (Pediatrics))
Figure 14.6. Blincyto®: Product Website Snapshots (Messages for Patients)
Figure 14.7. Blincyto®: Amgen Assist 360 Nurse Ambassador
Figure 14.8. Blincyto®: Presence in Conferences
Figure 14.9. Hemlibra®: Product Website Snapshots (Messages for Healthcare Professionals, Hemophilia A without Factor VIII Inhibitors)
Figure 14.10. Hemlibra®: Product Website Snapshots (Messages for Healthcare Professionals, Hemophilia A with Factor VIII Inhibitors)
Figure 14.11. Hemlibra®: Product Website Snapshots (Messages for Patients)
Figure 14.12. Hemlibra®: Presence in Conferences
Figure 15.1. Global Bispecific Antibody Therapeutics Market, 2023-2035 (USD Million)
Figure 15.2. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 15.3. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, 2023 and 2035 (USD Million)
Figure 15.4. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, 2023 and 2035 (USD Million)
Figure 15.5. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, 2023 and 2035 (USD Million)
Figure 15.6. Bispecific Antibody Therapeutics Market: Distribution by Key Players, 2023 and 2035 (USD Million)
Figure 15.7. Bispecific Antibody Therapeutics Market: Distribution by Geography, 2023 and 2035 (USD Million)
Figure 15.8. AK104 (Akeso Biopharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.9. Blincyto® (Amgen) Sales Forecast, Till 2035 (USD Million)
Figure 15.10. Hemlibra® (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.11 Kimmtrak® (Immunocore) Sales Forecast, Till 2035 (USD Million)
Figure 15.12. Lunsumio® (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.13. Nanozora® (Taisho Pharmaceutical) Sales Forecast, Till 2035 (USD Million)
Figure 15.14. Rybrevant™ (Janssen Research & Development) Sales Forecast, Till 2035 (USD Million)
Figure 15.15. Tecvayli™ (Janssen Research & Development) Sales Forecast, Till 2035 (USD Million)
Figure 15.16. Vabysmo™ (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.17. AK112 (Akeso Biopharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.18. ALXN1720 (Alexion) Sales Forecast, Till 2035 (USD Million)
Figure 15.19. GEN3013 (Genmab) Sales Forecast, Till 2035 (USD Million)
Figure 15.20. Glofitamab (Roche) Sales Forecast, Till 2035 (USD Million)
Figure 15.21. LP000 (Linton Pharm) Sales Forecast, Till 2035 (USD Million)
Figure 15.22. M7824 (Merck) Sales Forecast, Till 2035 (USD Million)
Figure 15.23. OMP 305B83 (Mereo BioPharma) Sales Forecast, Till 2035 (USD Million)
Figure 15.24. PF-06863135 (Pfizer) Sales Forecast, Till 2035 (USD Million)
Figure 15.25. ZW25 (Zymeworks) Sales Forecast, Till 2035 (USD Million)
Figure 16.1. Bispecific Antibody Therapeutics: SWOT Analysis
Figure 16.2. Comparison of SWOT Factors: Harvey Ball Analysis

List Of Tables

Table 3.1. Isotypes of Mammalian Antibodies
Table 3.2. Mechanisms of Action of Antibody Therapeutics
Table 3.3. Revenue of Top Antibody Therapeutics, 2022 (USD Billion)
Table 4.1. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Developer(s), Phase of Development and Target Antigen
Table 4.2. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Type of Therapy, Route of Administration and Method of Administration
Table 4.3. Bispecific Antibody Therapeutics: Information on Approved and Clinical Drug Candidates, Target Indication(s), Therapeutic Area(s) and Disease Segment(s)
Table 4.4. Bispecific Antibody Therapeutics Developers: Information on Approved and Clinical Drug Candidates Developers, Year of Establishment, Company Size, Location of Headquarters
Table 5.1. Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidates, Developer(s), Stage of Development and Target Antigen
Table 5.2. Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidates, Developer(s), Therapeutic Area(s) and Disease Segment(s)
Table 5.3. Bispecific Antibody Therapeutics Developers: Information on Preclinical Drug Candidates Developers, Year of Establishment, Company Size, Location of Headquarters
Table 7.1. Bispecific Antibody Therapeutics: List of Technology Platforms
Table 9.1. Bispecific Antibody Therapeutics Developers: List of Companies Profiled
Table 9.2. Akeso Biopharma: Company Overview
Table 9.3. Akeso Biopharma: Bispecific Antibody Therapeutics Portfolio
Table 9.4. Akeso Biopharma: Recent Developments and Future Outlook
Table 9.5. Alphamab Oncology: Company Overview
Table 9.6. Alphamab Oncology: Bispecific Antibody Therapeutics Portfolio
Table 9.7. Alphamab Oncology: Recent Developments and Future Outlook
Table 9.8. Amgen: Company Overview
Table 9.9. Amgen: Bispecific Antibody Therapeutics Portfolio
Table 9.10. Amgen: Recent Developments and Future Outlook
Table 9.11. Merck: Company Overview
Table 9.12. Merck: Bispecific Antibody Therapeutics Portfolio
Table 9.13. Merck: Recent Developments and Future Outlook
Table 9.14. Regeneron: Company Overview
Table 9.15. Regeneron: Bispecific Antibody Therapeutics Portfolio
Table 9.16. Regeneron: Recent Developments and Future Outlook
Table 9.17. Roche: Company Overview
Table 9.18. Roche: Bispecific Antibody Therapeutics Portfolio
Table 9.19. Roche: Recent Developments and Future Outlook
Table 9.20. Xencor: Company Overview
Table 9.21. Xencor: Bispecific Antibody Therapeutics Portfolio
Table 9.22. Xencor: Recent Developments and Future Outlook
Table 10.1. Partnerships and Collaborations: Information on Year of Agreement, Partner and Type of Agreement, 2016-2023
Table 10.2. Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2023
Table 11.1. List of Bispecific Antibody CMOs: Company Specifications
Table 11.2. List of Bispecific Antibody CMOs: Information on Scale of Operation
Table 11.3. List of Bispecific Antibody CROs: Company Specifications
Table 11.4. List of Bispecific Antibody CROs: Information on Type of Service
Table 11.5. Comparison of Key Factors for the Selection of Contract Service Provider: Harvey Ball Analysis
Table 14.1. List of Bispecific Antibodies Approved Across Various Geographies
Table 15.1. Bispecific Antibody Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
Table 15.2. AK104: Target Patient Population
Table 15.3. AK104: Net Present Value (USD Million)
Table 15.4. AK104: Value Creation Analysis (USD Million)
Table 15.5. Blincyto®: Target Patient Population
Table 15.6. Blincyto®: Net Present Value (USD Million)
Table 15.7. Blincyto®: Value Creation Analysis (USD Million)
Table 15.8. Hemlibra®: Target Patient Population
Table 15.9. Hemlibra®: Net Present Value (USD Million)
Table 15.10. Hemlibra®: Value Creation Analysis (USD Million)
Table 15.11. Kimmtrak®: Target Patient Population
Table 15.12. Kimmtrak®: Net Present Value (USD Million)
Table 15.13. Kimmtrak®: Value Creation Analysis (USD Million)
Table 15.14. Lunsumio®: Target Patient Population
Table 15.15. Lunsumio®: Net Present Value (USD Million)
Table 15.16. Lunsumio®: Value Creation Analysis (USD Million)
Table 15.17. Nanozora®: Target Patient Population
Table 15.18. Nanozora®: Net Present Value (USD Million)
Table 15.19. Nanozora®: Value Creation Analysis (USD Million)
Table 15.20. Rybrevant™: Target Patient Population
Table 15.21. Rybrevant™: Net Present Value (USD Million)
Table 15.22. Rybrevant™: Value Creation Analysis (USD Million)
Table 15.23. Tecvayli™: Target Patient Population
Table 15.24. Tecvayli™: Net Present Value (USD Million)
Table 15.25. Tecvayli™: Value Creation Analysis (USD Million)
Table 15.26. Vabysmo™: Target Patient Population
Table 15.27. Vabysmo™: Net Present Value (USD Million)
Table 15.28. Vabysmo™: Value Creation Analysis (USD Million)
Table 15.29. AK112: Target Patient Population
Table 15.30. AK112: Net Present Value (USD Million)
Table 15.31. AK112: Value Creation Analysis (USD Million)
Table 15.32. ALXN1720: Target Patient Population
Table 15.33. ALXN1720: Net Present Value (USD Million)
Table 15.34. ALXN1720: Value Creation Analysis (USD Million)
Table 15.35. GEN3013: Target Patient Population
Table 15.36. GEN3013: Net Present Value (USD Million)
Table 15.37. GEN3013: Value Creation Analysis (USD Million)
Table 15.38. Glofitamab: Target Patient Population
Table 15.39. Glofitamab: Net Present Value (USD Million)
Table 15.40. Glofitamab: Value Creation Analysis (USD Million)
Table 15.41. LP000: Target Patient Population
Table 15.42. LP000: Net Present Value (USD Million)
Table 15.43. LP000: Value Creation Analysis (USD Million)
Table 15.44. M7824: Target Patient Population
Table 15.45. M7824: Net Present Value (USD Million)
Table 15.46. M7824: Value Creation Analysis (USD Million)
Table 15.47. OMP 305B83: Target Patient Population
Table 15.48. OMP 305B83: Net Present Value (USD Million)
Table 15.49. OMP 305B83: Value Creation Analysis (USD Million)
Table 15.50. PF-06863135: Target Patient Population
Table 15.51. PF-06863135: Net Present Value (USD Million)
Table 15.52. PF-06863135: Value Creation Analysis (USD Million)
Table 15.53. ZW25: Target Patient Population
Table 15.54. ZW25: Net Present Value (USD Million)
Table 15.55. ZW25: Value Creation Analysis (USD Million)
Table 18.1. CytomX Therapeutics: Company Snapshot
Table 18.2. F-star: Company Snapshot
Table 18.3. Immunai: Company Snapshot
Table 18.4. Innovent Biologics: Company Snapshot
Table 18.5. SYNIMMUNE: Company Snapshot
Table 18.6. University of Freiburg: Organization Snapshot
Table 19.1. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 19.2. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Table 19.3. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Type of Therapy
Table 19.4. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Route of Administration
Table 19.5. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Method of Administration
Table 19.6. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Table 19.7. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Therapeutic Area
Table 19.8. Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Table 19.9. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Table 19.10. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Table 19.11. Approved and Clinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Table 19.12. Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Table 19.13. Preclinical Bispecific Antibody Therapeutics: Distribution by Target Antigen
Table 19.14. Preclinical Bispecific Antibody Therapeutics: Distribution by Disease Segment
Table 19.15. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Year of Establishment
Table 19.16. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Company Size
Table 19.17. Preclinical Bispecific Antibody Therapeutics Developers: Distribution by Location of Headquarters
Table 19.18. Most Popular Technology Platforms: Distribution by Stage of Development
Table 19.19. Bispecific Antibody Technology Platform Developers: Distribution by Location of Headquarters
Table 19.20. Akeso Biopharma: Annual Revenues, 2019 - 2022 (RMB Million)
Table 19.21. Alphamab Oncology: Annual Revenues, 2019 - H1 2022 (RMB Million)
Table 19.22. Amgen: Annual Revenues, 2019 - 2022 (USD Billion)
Table 19.23. Merck: Annual Revenues, 2019 - H1 2022 (EUR Billion)
Table 19.24. Regeneron: Annual Revenues, 2019 - 2022 (USD Billion)
Table 19.25. Roche: Annual Revenues, 2019 - 2022 (CHF Million)
Table 19.26. Xencor: Annual Revenues, 2019 - 2022 (USD Million)
Table 19.27. Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2023
Table 19.28. Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.29. Partnerships and Collaborations: Distribution by Disease Segment
Table 19.30. Partnerships and Collaborations: Distribution by Type of Payment Model Employed and Deal Amount (USD Billion)
Table 19.31. Partnerships and Collaborations: Year-wise Distribution by Type of Payment Model Employed and Deal Amount (USD Billion, 2016-2023)
Table 19.32. Partnerships and Collaborations: Distribution by Disease Segment, Type of Payment Model Employed and Deal Amount (USD Billion)
Table 19.33. Most Active Players: Distribution by Number of Partnership Instances
Table 19.34. Most Popular Technologies: Distribution by Number of Partnership Instances
Table 19.35. Partnerships and Collaborations: Distribution by Region
Table 19.36. Partnerships and Collaborations: International and Intracontinental Agreements
Table 19.37. Clinical Trial Analysis: Cumulative Year-wise Trend of Trials by Trial Registration Year, Pre-2010-2023
Table 19.38. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2010-2023
Table 19.39. Clinical Trial Analysis: Distribution by Trial Phase
Table 19.40. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.41. Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 19.42. Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year and Trial Recruitment Status
Table 19.43. Clinical Trial Analysis: Distribution by Type of Study
Table 19.44. Clinical Trial Analysis: Distribution by Study Design
Table 19.45. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.46. Clinical Trial Analysis: Geographical Distribution by Trial Recruitment Status
Table 19.47. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population by Trial Recruitment Status
Table 19.48. Global Bispecific Antibody Therapeutics Market, Conservative, Base, and Optimistic Scenarios, 2023-2035 (USD Million)
Table 19.49. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.50. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.51. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.52. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.53. Bispecific Antibody Therapeutics Market: Distribution by Key Players, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.54. Bispecific Antibody Therapeutics Market: Distribution by Geography, Conservative, Base, and Optimistic Scenarios, 2023 and 2035 (USD Million)
Table 19.55. AK104 (Akeso Biopharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.56. Blincyto® (Amgen) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.57. Hemlibra® (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.58. Kimmtrak® (Immunocore) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.59. Lunsumio® (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.60. Nanozora® (Taisho Pharmaceutical) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.61. Rybrevant™ (Janssen Research & Development) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.62. Tecvayli™ (Janssen Research & Development) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.63. Vabysmo™ (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.64. AK112 (Akeso Biopharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.65. ALXN1720 (Alexion) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.66. GEN3013 (Genmab) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.67. Glofitamab (Roche) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.68. LP000 (Linton Pharm) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.69. M7824 (Merck) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.70. OMP 305B83 (Mereo BioPharma) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.71. PF-06863135 (Pfizer) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)
Table 19.72. ZW25 (Zymeworks) Sales Forecast, Till 2035, Conservative, Base, and Optimistic Scenarios (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

23andMe
3D Medicines
Ab Therapeutics
AbbVie
AbCellera
AbClon
ABL Bio
Ablynx (Acquired by Sanofi)
Abpro
ACELYRIN
Adagene
ADC Therapeutics
Adimab
Affibody
Affimed
Agenus
Akamis Bio (Formerly known as PsiOxus Therapeutics)
Akeso Biopharma
Alexion
Alligator Bioscience
Almirall
Alphamab Oncology
Amgen
Antengene
AP Biosciences
Applied BioMath
Aprogen
Aptevo Therapeutics
Arbele
ArsenalBio
Artiva Biotherapeutics
Astellas Pharma
AstraZeneca
Atreca
Avacta
AvenCell
Avillion
Baliopharm (Acquired by Promethera Biosciences)
BeiGene
Beta Pharma
Bicara Therapeutics
Biocytogen
Biogen
BioInvent
BIOMUNEX
BiOneCure Therapeutics
BioNTech
Bio-Thera Solutions
Biotheus
BiVictriX Therapeutics
BliNK Biomedical
Boehringer Ingelheim
Bolt Biotherapeutics
Boston Pharmaceuticals
Bristol Myers Squibb
Cancer Research UK
Caris Life Sciences
Celgene
Celldex Therapeutics
Celltrion
Celularity
CentryMed
Chimagen Biosciences
Chugai Pharmaceutical
Compass Therapeutics
Context Therapeutics
Crescendo Biologics
CSPC Pharmaceutical
CTM Biotech (Acquired by Alpha Biologics)
CytomX Therapeutics
Cytovia Therapeutics
Daiichi Sankyo
Dana-Farber Cancer Institute
Dragonfly Therapeutics
Dren Bio
Dualogics
Eddingpharm
Eli Lily
Elpiscience
EngMab
EpimAb Biotherapeutics
Eutilex
ExcelmAb
Exelixis
FineImmune
F-star
Gadeta
GE Healthcare
Genedata
Genentech
Genmab
Genor Biopharma
GenScript ProBio
Gilead Sciences
GlaxoSmithKline
Glenmark Pharmaceuticals
HALIX
Handok
Hangzhou Zhongmei Huadong Pharmaceutical
Hanmi Pharmaceutical
Hansoh Pharmaceutical
Harbour BioMed
Hemogenyx Pharmaceuticals
Huabo Biopharm
Hualan Biological Engineering
Image Analysis Group (IAG)
Ichnos Sciences
IGM Biosciences
I-Mab Biopharma
Immatics
ImmuneOncia
Immunoah Therapeutics
Immunocore
ImmunoPrecise Antibodies
Incyte
INGENIA Therapeutics
Inhibrx
Inmagene
Innate Pharma
InnoCare Pharma
Innovent Biologics
Inserm
Integral Molecular
Intract Pharma
Invenra
invoX Pharma
Ipsen
Janssen
Janux Therapeutics
Jazz Pharmaceuticals
Jounce Therapeutics
Kenjockety Biotechnology
Keymed Biosciences
King’s College London
Kintor Pharmaceutical
Kite Pharma (Acquired by Gilead Sciences)
KLUS Pharma
LamKap Bio
Lava Therapeutics
LeadArtis
Leads Biolabs
LegoChem Biosciences
LEO Pharma
Light Chain Bioscience
Lindis Biotech
LintonPharm
Lonza
Loxo Oncology
MAbSilico
MAB Works
MacroGenics
Marengo Therapeutics
Massachusetts Institute of Technology
MD Anderson Cancer Centre
MediaPharma
Medison Pharma
Memorial Sloan Kettering Cancer Center
Merck
Mereo BioPharma
Merus
Molecular Partners
Multitude Therapeutics
MUSTBIO
NGM Biopharmaceuticals
Nona Biosciences
NovalGen
Novartis
Novimmune
OncXerna Therapeutics (Formerly known as Oncologie)
Ono Pharmaceutical
Onward Therapeutics
Orion BioScience
OSE Immunotherapeutics
Ossianix
Oxford BioTherapeutics
Pascal Biosciences
Pfizer
Phanes Therapeutics
PharmAbcine
Pieris Pharmaceuticals
ProBioGen
Provention Bio
QIMR Berghofer Medical Research Institute
QLSF Biotherapeutics
QureBio
Regeneron Pharmaceuticals
Rentschler Biopharma
Roche
Roivant Sciences
Sanofi
Sea Lane Biotechnologies
Seagen
Selexis
Sema4
Servier
Henlius
Simcere
SpringWorks Therapeutics
STC Biologics
Summit Therapeutics
Surrozen
Systimmune
Taisho Pharmaceutical
Takeda Pharmaceutical
Tasly Biopharmaceuticals
Teneobio (Acquired by Amgen)
TeneoOne (Acquired by AbbVie)
TeneoTwo (Acquired by AstraZeneca)
TG Therapeutics
Transcenta
TRIGR Therapeutics (Acquired by Compass Therapeutics)
University of Oxford
University of Surrey
Viva BioInnovator
Vor Bio
WuXi Biologics
Xencor
Y-Biologics
Y-mAbs Therapeutics
Yuhan
Zai Lab
Zenas BioPharma
Zymeworks

Source 1: https://www.frontiersin.org/articles/10.3389/fimmu.2021.626616/full

PRICING DETAILS

Single-User License USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

One Location Site License USD 7,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Enterprise License USD 17,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

Bispecific Antibodies Market